Hydreight Technologies Q3 2025: Revenue Soars but EPS Slightly Below Street Expectations

Hydreight Technologies Inc. (TSXV: NURS / OTCQB: HYDTF) reported its Q3 2025 earnings, delivering a strong top‑line increase — but falling a bit short on earnings per share. 🧾 Financials at a glance GAAP revenue reached CA$10.52 million for the quarter, up 132% year‑over‑year, missing the consensus by about CA$2.77M. Adjusted (non‑GAAP) topline was CA$12.83 million, a 110% increase vs Q3 2024. Gross margin grew to CA$2.33 million, up from CA$1.53 million a year earlier. The company posted a GAAP net income of CA$362,000, compared with a net loss of CA$90,000 in Q3 2024 — marking its fourth consecutive profitable quarter. 📈 What’s behind the growth Hydreight’s momentum is largely driven by strong adoption of its VSDHOne direct‑to‑consumer telehealth platform. The period saw nearly 295,000 VSDHOne product orders processed, spanning services like GLP‑1 weight‑management, hormone therapy, NAD, hair restoration, genetic testing, and more. On the operational front, the company expanded its nurse network aggressively — registering 198 new nurse sign-ups this quarter (versus 133 in the same quarter last year, up ~49% YoY) — and grew pharmacy orders by ~72% year‑over‑year, showing broader adoption across multiple wellness verticals. 🔧 Strategic moves & future outlook Hydreight also continues to invest in infrastructure and partnerships: it signed a definitive agreement to acquire a 5% equity stake (with option to go to 40%) in Perfect Scripts, LLC, aiming to deepen its reach in the telehealth/pharmacy space. The company highlighted that VSDHOne will be enhanced in upcoming versions with better automation, modular architecture, and expanded partner integrations — all aimed at scaling operations nationwide and supporting aggressive 2026 growth objectives. At quarter-end, Hydreight held CA$18.64 million in cash, giving it solid liquidity to support expansion. In short: despite a modest EPS miss, Hydreight’s explosive revenue growth, improving margins, and execution on its telehealth‑first strategy suggest it’s building serious momentum heading into 2026. #Hydreight #Telehealth #VSDHOne #HealthcareGrowth #SlimScan #GrowthStocks #CANSLIM